This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Will Veracyte (VCYT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Veracyte Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Veracyte.
Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 38.46% and 5.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: Radiant, Great Lakes, Clarus, Veracyte and First BanCorp
by Zacks Equity Research
Zacks.com featured highlights include: Radiant, Great Lakes, Clarus, Veracyte and First BanCorp
5 Stocks With Recent Price Strength to Maximize Your Gains
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Will Veracyte (VCYT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Veracyte (VCYT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 50.00% and 9.06%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Veracyte (VCYT) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Veracyte (VCYT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Veracyte (VCYT) stock based on the movements in the options market lately.
Zacks.com featured highlights include: OFG, Northern Oil, Sunrun, Cerus and Veracyte
by Zacks Equity Research
Zacks.com featured highlights include: OFG, Northern Oil, Sunrun, Cerus and Veracyte
5 Breakout Stocks Offering Stellar Returns
by Swarup Gupta
This involves zeroing in on stocks trading within a tight band and buying them when they move out of this band.
Are Options Traders Betting on a Big Move in Veracyte (VCYT) Stock?
by Zacks Equity Research
Investors in Veracyte (VCYT) need to pay close attention to the stock based on moves in the options market lately.
5 MedTech Stocks to Pick for Stellar Returns
by Zacks Equity Research
While the MedTech industry has been grappling with multiple issues, these stocks with high growth potential can be great bets.
5 Top-Ranked MedTech Growth Stocks for Solid Returns
by Zacks Equity Research
Despite the ongoing turmoil in the MedTech industry, these stocks with high growth potential can be great bets for investors.
Quest Diagnostics Partners with Veracyte for Cancer Testing
by Zacks Equity Research
Quest Diagnostics Incorporated (DGX) has recently entered into an agreement with genomic diagnostics company Veracyte, Inc. (VCYT), for the extended access of Afirma Gene Expression Classifier (GEC).
4 Growth Stocks to Buy Amid Obamacare Repeal Talks
by Zacks Equity Research
Affordable Care Act (ACA) has been one of the most discussed topics during the 2016 U.S. presidential election. Even after a month, it has been contributing to the discord in the healthcare investment market.